Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Luseco
Synonyms :
Luseogliflozin, TS 071, TS- 71, TS- 071
Class :
SGLT2 inhibitor
Brand Name :
Luseco
Synonyms :
Luseogliflozin, TS 071, TS- 71, TS- 071
Class :
SGLT2 inhibitor
Dosage Forms &Â Â StrengthsÂ
Tablets (film-coated)Â
2.5mgÂ
5mgÂ
2.5
mg
Orally 
every 24 hours
Note: the dose can be increased to 5mg depending on the response of the patient
Safety and  efficacy studies are not establishedÂ
Refer to adult dosingÂ
2.5
mg
Orally 
every 24 hours
Note: this should be used with caution in elderly population as the physiological function in these population may be altered
the hypoglycemic activity of acarbose may be increased
the therapeutic effects of acebutolol may be enhanced
the therapeutic efficacy of luseogliflozin may be elevated
the hypoglycemic efficiency of albiglutide can be increased
the hypoglycemic effect of alogliptin may be enhanced
an increase in hypoglycemic effects of luseogliflozin may be seen
the risk of hyperglycemia may be enhanced
the hypoglycemic effects of luseogliflozin may be reduced
the hypoglycemic activity of luseogliflozin may be increased
the therapeutic activity of luseogliflozin may be reduced
the therapeutic efficiency of luseogliflozin may be elevated
the risk of hyperglycemia may be enhanced
the hypoglycemic effect of canagliflozin may be increased
the risk of renal failure hyperkalemia and hypotension may be raised
the hypoglycemic activity of chlorpropamide may be increased
the risk of hyperglycemia may be enhanced
Actions and spectrum:Â
Luseogliflozin is an antidiabetic drug. It works by stopping a protein called SGLT2  from absorbing too much glucose back into the body from the kidneys at the proximal tubules. By blocking SGLT2, luseogliflozin  allows excess glucose to be excreted from the body through urine. In laboratory studies, luseogliflozin selectively inhibited glucose uptake by human SGLT2 cells.Â
Frequency not definedÂ
Genital  candidiasisÂ
PolycythaemiaÂ
DehydrationÂ
DizzinessÂ
PolyuriaÂ
Pruritis genitalÂ
ThirstÂ
CystitisÂ
PyelonephritisÂ
HypotensionÂ
KetoacidosisÂ
Black Box WarningÂ
No specific black box warning is documentedÂ
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Special precautions:Â
Renal impairmentÂ
Hepatic impairmentÂ
PolyuriaÂ
PollakiuriaÂ
Genital infectionsÂ
Infections of the urinary tractÂ
KetoacidosisÂ
Pregnancy/LactationÂ
Pregnancy consideration:Â
Safety and efficiency about the use  of luseogliflozin in pregnant people is not establishedÂ
Lactation:Â
It should not be used in lactating mothers as the medication is known to be secreted into breast milk.Â
Formula feed should be given to the infants if luseogliflozin should be administered to motherÂ
Pregnancy categories:Â
Category A: Studies that were well-controlled and  met expectations revealed no risk to the foetus `in either the first or  second trimester.Â
Category B: There was a lack of studies on pregnant  women and no evidence of risk to the foetus in animal experiments.Â
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.Â
Category D: adequate data with sufficient evidence  of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.Â
Category X: Drugs listed in this category outweigh  the risks over benefits. Hence these categories of drugs need to be avoided  by pregnant women.Â
Category N: There is no data available for the  drug under this categoryÂ
Pharmacology:Â
Luseogliflozin is a novel chemical  entity possessing strong inhibitory activity against sodium-dependent glucose  cotransporter2.Â
Pharmacodynamics:Â
This is a selective inhibitor of  SGLT2. It promotes urinary glucose excretion that leads to lowered levels  of glucose in plasma. In people with type 2 diabetes mellitus, luseogliflozin provides  a noticeable glycemic control.Â
Pharmacokinetics:Â
AbsorptionÂ
Luseogliflozin is absorbed rapidly  on oral absorption.Â
DistributionÂ
96% of the drug is known to be bound  to plasma proteins.Â
MetabolismÂ
The drug undergoes hepatic  metabolism via CYP3A4/5. The main metabolites exist is carboxyl and O-deethyl  form.Â
Elimination and excretionÂ
It is known to undergo elimination through urine.Â
Administration:Â
Luseogliflozin should be administered orally  onetime a day before or after meals.Â
Patient information leafletÂ
Generic Name: luseogliflozinÂ
Pronounced: loo-se-oo-gli-flow-jinÂ
Why do we  use luseogliflozin?Â
Luseogliflozin (TS-071) is a unique medicine that works very well at stopping the SGLT2 protein from letting sugar into the body. This medicine helps lower blood sugar levels. It was approved for use in Japan. Patients can take it alone or with other diabetes drugs.Â
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
